Bacterial Extracellular Vesicle Quantification for Intestinal Barrier Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for intestinal barrier permeability and gut microbial dysbiosis, which are crucial for diagnosing and monitoring inflammatory diseases such as HIV, IBD, and cancer, as they fail to accurately quantify bacterial extracellular vesicles and their associated molecular patterns in biofluids.
Innovation Solution
An in vitro method involving the isolation of bacterial extracellular vesicles from biofluids, quantification of LPS and LTA activity, and determination of 16S rRNA content, which correlates with intestinal barrier permeability and microbial dysbiosis, using techniques like size exclusion chromatography, density gradient centrifugation, and reporter assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If bacterial extracellular vesicles are isolated and quantified from biofluids, then diagnostic accuracy for intestinal barrier permeability and microbial dysbiosis is improved, but measurement precision and detection capability are currently insufficient
Solution Approach 1:
The patent extracts bacterial extracellular vesicles from complex biofluid samples through differential centrifugation and filtration steps, isolating the target particles from interfering substances. This extraction enables subsequent precise quantification by removing matrix effects that would otherwise compromise measurement accuracy
Solution Approach 2:
The patent employs molecular patterns (LPS, LTA, 16S rRNA) as intermediary markers that can be detected within bacterial EVs. These molecular intermediaries serve as reliable proxies for EV quantification, allowing indirect but highly accurate measurement of bacterial translocation and gut barrier status
2Reliability
If current methods are used to assess intestinal barrier permeability, then diagnostic simplicity is maintained, but reliability of disease diagnosis and monitoring is insufficient
Solution Approach 1:
The diagnostic approach is segmented into distinct analytical components: isolation of bacterial EVs, quantification of specific molecular patterns (LPS, LTA, 16S rRNA), and interpretation of results in clinical context. This segmentation allows each step to be optimized and validated independently, enhancing overall diagnostic reliability
Solution Approach 2:
The patent establishes a universal diagnostic platform using bacterial EV molecular patterns that can assess multiple conditions simultaneously - intestinal barrier permeability, microbial dysbiosis, and systemic inflammation. This multi-functional approach increases diagnostic reliability across different inflammatory diseases without proportionally increasing complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively determines intestinal barrier permeability and gut microbial dysbiosis, providing a biomarker for diagnosing and monitoring inflammatory diseases by quantifying bacterial EVs and their molecular patterns, thus aiding in therapeutic response monitoring and intervention assessment.
Implementation Method 1
using techniques like size exclusion chromatography, density gradient centrifugation
Implementation Method 2
using techniques like size exclusion chromatography, density gradient centrifugation
Data Source
AI summary
The present disclosure relates to a method of analyzing a biofluid of a subject for the presence of bacterial extracellular vesicles (EV), the method comprising the steps of a) extracting bacterial EV from the biofluid, b) analyzing the bacterial EV-extracted molecular patterns for the presence of a disease marker, wherein the disease marker is a disease-specific molecular pattern of the subject; and the subject comprising patients diagnosed with HIV, IBD or cancer or the subject receiving a treatment.